The recently finalized Pregnancy Labeling and Lactation Labeling Rule changes the organization of the current Pregnancy and Nursing Mothers section of the US package insert of prescription drugs. In response to these changes in prescription drug labeling, the HESI Developmental and Reproductive Toxicology (DART) Technical committee sponsored a two-day workshop on this topic.
Developing and using specific imaging technologies (e.g., micro-CT, MRI) allows for alternative methods for evaluating structural birth defects in animal models.
This event was sponsored by the HESI Protein Allergenicity Technical Committee (PATC).
In February 2015, Syril Pettit, Executive Director of HESI, traveled to Tokyo, Japan for an outreach visit.